Alteration of the lysophosphatidic acid and its precursor lysophosphatidylcholine levels in spinal cord stenosis: A study using a rat cauda equina compression model

[1]  A. Saxena,et al.  Emerging Treatments , 2021, Bone Stress Injuries.

[2]  Eduardo García España.  Terminology , 1973, Hybrid Nuclear Energy Systems.

[3]  Sakae Tanaka,et al.  Lysophosphatidic acids and their substrate lysophospholipids in cerebrospinal fluid as objective biomarkers for evaluating the severity of lumbar spinal stenosis , 2019, Scientific Reports.

[4]  J. Aoki,et al.  Conductive Adhesive Film Expands the Utility of Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging. , 2019, Analytical chemistry.

[5]  N. Knezevic,et al.  Neurogenic Claudication: a Review of Current Understanding and Treatment Options , 2019, Current Pain and Headache Reports.

[6]  M. Sumitani,et al.  Lysophosphatidic acid is associated with neuropathic pain intensity in humans: An exploratory study , 2018, PloS one.

[7]  H. Ueda.  Lysophosphatidic acid signaling is the definitive mechanism underlying neuropathic pain. , 2017, Pain.

[8]  S. Ohtori,et al.  Pregabalin for Refractory Radicular Leg Pain due to Lumbar Spinal Stenosis: A Preliminary Prospective Study , 2016, Pain research & management.

[9]  E. Benzel,et al.  Membrane-Stabilizing Agents Improve Quality-of-Life Outcomes for Patients with Lumbar Stenosis , 2015, Global spine journal.

[10]  N. Lago,et al.  Activation of Lysophosphatidic Acid Receptor Type 1 Contributes to Pathophysiology of Spinal Cord Injury , 2015, The Journal of Neuroscience.

[11]  Mushfiquddin Khan,et al.  Oral administration of cytosolic PLA2 inhibitor arachidonyl trifluoromethyl ketone ameliorates cauda equina compression injury in rats , 2015, Journal of Neuroinflammation.

[12]  H. Daida,et al.  Possible Involvement of Minor Lysophospholipids in the Increase in Plasma Lysophosphatidic Acid in Acute Coronary Syndrome , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[13]  E. J. Cobos,et al.  “Bedside-to-Bench” Behavioral Outcomes in Animal Models of Pain: Beyond the Evaluation of Reflexes , 2013, Current neuropharmacology.

[14]  J. Chun,et al.  Lysophospholipids and their receptors in the central nervous system. , 2013, Biochimica et biophysica acta.

[15]  S. David,et al.  Harmful and beneficial effects of inflammation after spinal cord injury: potential therapeutic implications. , 2012, Handbook of clinical neurology.

[16]  D. Escalante-Alcalde,et al.  Lysophosphatidic acid directly activates TRPV1 through a C-terminal binding site. , 2013, Nature chemical biology.

[17]  H. Ueda,et al.  Pre‐emptive morphine treatment abolishes nerve injury‐induced lysophospholipid synthesis in mass spectrometrical analysis , 2011, Journal of neurochemistry.

[18]  H. Flor,et al.  Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes , 2010, PAIN.

[19]  M. Ohmura,et al.  Paradoxical ATP elevation in ischemic penumbra revealed by quantitative imaging mass spectrometry. , 2010, Antioxidants & redox signaling.

[20]  Christina C. Pegg,et al.  Technique for collection of cerebrospinal fluid from the cisterna magna in rat , 2010, Journal of Neuroscience Methods.

[21]  O. Kasimcan,et al.  Efficacy of gabapentin for radiculopathy caused by lumbar spinal stenosis and lumbar disk hernia. , 2010, Neurologia medico-chirurgica.

[22]  Harald Prüss,et al.  Lumbar spinal stenosis: syndrome, diagnostics and treatment , 2009, Nature Reviews Neurology.

[23]  J. Aoki,et al.  Two pathways for lysophosphatidic acid production. , 2008, Biochimica et biophysica acta.

[24]  R. Treede,et al.  The Kyoto protocol of IASP Basic Pain Terminology , 2008, PAIN®.

[25]  A. Dray,et al.  Neuropathic pain: emerging treatments. , 2008, British journal of anaesthesia.

[26]  H. Ueda.  Peripheral mechanisms of neuropathic pain – involvement of lysophosphatidic acid receptor-mediated demyelination , 2008, Molecular pain.

[27]  H. Ikeda,et al.  Suppression of lysophosphatidic acid and lysophosphatidylcholine formation in the plasma in vitro: proposal of a plasma sample preparation method for laboratory testing of these lipids. , 2007, Analytical biochemistry.

[28]  X. Navarro,et al.  Neural plasticity after peripheral nerve injury and regeneration , 2007, Progress in Neurobiology.

[29]  M. Sekiguchi,et al.  Spinal stenosis: assessment of motor function, VEGF expression and angiogenesis in an experimental model in the rat , 2007, European Spine Journal.

[30]  Misha-Miroslav Backonja,et al.  Classification of patients with pain based on neuropathic pain symptoms: Comparison of an artificial neural network against an established scoring system , 2007, European journal of pain.

[31]  L. Özgönenel,et al.  The Efficiency of Gabapentin Therapy in Patients With Lumbar Spinal Stenosis , 2007, Spine.

[32]  W. Moolenaar,et al.  Regulation and biological activities of the autotaxin-LPA axis. , 2007, Progress in lipid research.

[33]  H. Ueda.  [Lysophosphatidic acid as initiator of neuropathic pain]. , 2011, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[34]  J. Katz,et al.  Lumbar disc disorders and low-back pain: socioeconomic factors and consequences. , 2006, The Journal of bone and joint surgery. American volume.

[35]  H. Ueda.  Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms. , 2006, Pharmacology & therapeutics.

[36]  M. Vasko,et al.  Lipid mediators of sensitivity in sensory neurons. , 2005, Trends in pharmacological sciences.

[37]  M. Tsuda,et al.  Neuropathic pain and spinal microglia: a big problem from molecules in ‘small’ glia , 2005, Trends in Neurosciences.

[38]  J. Saba.  Lysophospholipids in development: Miles apart and edging in , 2004, Journal of cellular biochemistry.

[39]  G. Mills,et al.  The emerging role of lysophosphatidic acid in cancer , 2003, Nature Reviews Cancer.

[40]  N. Birkmeyer,et al.  Rates of Advanced Spinal Imaging and Spine Surgery , 2003, Spine.

[41]  Chantal Wouters,et al.  An exploratory study , 2003 .

[42]  G. Mills,et al.  Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production , 2002, The Journal of cell biology.

[43]  辻野 宏明.  Activating transcription factor 3 (ATF 3) induction by axotomy in sensory and motoneurons : a novel neuronal marker of nerve injury , 2000 .

[44]  Atsushi Tokunaga,et al.  Activating Transcription Factor 3 (ATF3) Induction by Axotomy in Sensory and Motoneurons: A Novel Neuronal Marker of Nerve Injury , 2000, Molecular and Cellular Neuroscience.

[45]  A. Brink,et al.  A preliminary prospective study , 1989 .